肝细胞癌患者报告结局:美国肝病研究学会实践指标委员会的范围综述
美国肝病研究学会实践指标委员会对1990至2021年肝细胞癌患者报告结局(PROs)进行范围综述,纳入63项研究,发现较差的PROs与更差预后及更晚期疾病相关,局部和全身治疗通常与高症状负担相关,但PROs融入临床决策、照护者影响及姑息支持治疗对生活质量和健康结局的作用尚存证据缺口。
要点
- 证据支持在肝细胞癌中评估患者报告结局。
- 较差的PROs与更差预后及更晚期疾病相关,但部分研究显示肝细胞癌患者PROs优于肝硬化患者。
- 局部和全身治疗通常与高症状负担相关,但经动脉放疗和放疗在部分研究中显示较低症状负担。
核心结论
- 证据支持在肝细胞癌中评估患者报告结局,但临床实施及PRO测量对照护质量和纵向结局的影响需未来研究。
研究设计与样本
- 美国肝病研究学会实践指标委员会对1990至2021年肝细胞癌患者报告结局进行范围综述,共63项研究符合纳入标准。
主要发现
- 较差的PROs在校正临床因素后与更差预后相关,并与更晚期疾病分期相关,但部分研究显示肝细胞癌患者PROs优于肝硬化患者。
- 局部和全身治疗通常与高症状负担相关,但部分研究显示经动脉放疗和放疗症状负担较低。
- 定性研究识别出结构化问卷未常规评估的额外症状。
关键数值与推荐
- 证据支持评估肝细胞癌患者报告结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 文献缺口包括缺乏将PROs融入临床照护以指导肝细胞癌治疗决策。
- 肝细胞癌对照护者的影响未知。
- 姑息或支持治疗对生活质量和健康结局的作用未知。
- PRO测量对照护质量和纵向结局的影响需未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: HCC is a leading cause of mortality in patients with advanced liver disease and is associated with significant morbidity. Despite multiple available curative and palliative treatments, there is a lack of systematic evaluation of patient-reported outcomes (PROs) in HCC. APPROACH AND RESULTS: The American Association for the Study of Liver Diseases Practice Metrics Committee conducted a scoping review of PROs in HCC from 1990 to 2021 to (1) synthesize the evidence on PROs in HCC and (2) provide recommendations on incorporating PROs into clinical practice and quality improvement efforts. A total of 63 studies met inclusion criteria investigating factors associated with PROs, the relationship between PROs and survival, and associations between HCC therapy and PROs. Studies recruited heterogeneous populations, and most were cross-sectional. Poor PROs were associated with worse prognosis after adjusting for clinical factors and with more advanced disease stage, although some studies showed better PROs in patients with HCC compared to those with cirrhosis. Locoregional and systemic therapies were generally associated with a high symptom burden; however, some studies showed lower symptom burden for transarterial radiotherapy and radiation therapy. Qualitative studies identified additional symptoms not routinely assessed with structured questionnaires. Gaps in the literature include lack of integration of PROs into clinical care to guide HCC treatment decisions, unknown impact of HCC on caregivers, and the effect of palliative or supportive care quality of life and health outcomes. CONCLUSION: Evidence supports assessment of PROs in HCC; however, clinical implementation and the impact of PRO measurement on quality of care and longitudinal outcomes need future investigation.
引用
- Serper M, Parikh ND, Thiele G, et al. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022. PMID: 34990516. doi:10.1002/hep.32313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。